From first-in-class allergen platforms to pre-clinical biologic programmes, HH Global Holdings designs and delivers diagnostic technologies and drug characterisation programmes that move science from bench to clinical or commercial readiness.
Selected examples of our work in diagnostic platform development, IP commercialisation, and pre-clinical drug characterisation programmes.
A single-device lateral flow test that detects 13 of the 14 EU-regulated allergens in 15 minutes, no instrument, no laboratory required. HH Global Holdings retains full IP and is in global licensing discussions with a major international diagnostics manufacturer.
An end-to-end pre-clinical programme that characterises a biologic drug, establishing what it is, how it works, and validating its efficacy, readying the asset for clinical entry, partnership, or licensing.